Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Cancer Res. 2015 Dec 16;76(3):675–685. doi: 10.1158/0008-5472.CAN-15-1141

Figure 1.

Figure 1

EZH2 was higher in tumors with a KRASG12C mutation compared with other KRAS mutant, and KRAS knockdown downregulates EZH2 expression in cell lines with KRAS mutant. A, Box plot of EZH2 expression of lung adenocarcinoma tumors with KRAS mutant (**P < 0.004). B, Representative photomicrographs of EZH2 immunohistochemical expression in NSCLC with different amino acids substituted on the KRAS mutant. C, EZH2 expression in NSCLC (left) and HBEC cell lines (right). D, KRAS and EZH2 expression in NSCLC cell lines upon knockdown of KRAS by treatment with siKRAS.